SLS
NASDAQ
$12.48
SELLAS Life Sciences Group Inc (SLS)
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $27.50 (+120.44%)
Market Cap
$2.32B
Free Cash Flow Yield
-1.21%
Beta (5Y)
0.90
Price Chart
Valuation
Market Cap$2.32B
P/S26.90
P/B23.41
Profitability
Gross Profit (TTM)$900K
EBITDA-$29M
EPS-$0.22
Financial Health
Free Cash Flow Yield-1.21%
Growth & Risk
EPS 5Y CAGR-32.56%
FCF 5Y CAGR+15.24%
Beta (5Y)0.90
Sharpe Ratio2.31